Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

AI Summary: Summit Therapeutics announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for Ivonescimab—intended for patients with EGFR‑mutated non‑small cell lung cancer who have progressed after TKI therapy. The regulatory nod signals a promising step forward in targeted lung cancer treatment.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA lifts holds on Intellia’s Phase 3 gene-editing trials / 2 months

FDA rejects Disc Medicine’s rare-disease drug despite priority review / 3 months

Axpaxli outperforms Eylea in Phase 3; FDA filing expected / 3 months

BridgeBio’s dwarfism drug posts positive Phase 3 data, FDA filing on track / 3 months

FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval / 3 months

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months